Skip to the content
  • Suomeksi
  • About us
    • > Our role
    • > BoD and management
    • > Sustainability
  • For pharma sector
    • > Research archive
  • Newsfeed
  • Contacts
  • Suomeksi

For pharma sector

We study vaccines with decades of experience and internationally recognized, high-quality scientific expertise. Our comprehensive network of ten clinics offers first-class prerequisites for this. We offer clinical expertise in phases 1-4 of vaccine research as well as investigations into the effectiveness and safety of vaccines already in use. We have strong expertise in Real-World Evidence (RWE) studies and pragmatic vaccine trials, utilizing Finland’s comprehensive health registers and data resources.

Study partner Net Promoter Score (NPS)*88 (excellent)
Keeping agreed schedules in vaccine studies*9.1/10
Reaching targets in vaccine studies*9.1/10
Study volunteer satisfaction** 94% (positive feedback)
(*Vaccine manufacturer and monitor satisfaction study 2023; **HappyOrNot feedback devices at clinics)

Why work with FVR – Finnish Vaccine Research?

  • High degree of subject matter expertise in phases 1-4 of vaccine research, including registry / RWE data and large-scale pragmatic studies.
  • National network of ten clinics with just one clinical trial agreement.
  • Core focus on clinical vaccine research: it is our one and only priority.
  • Approx. 100 GCP-qualified research experts across Finland, with decades of accumulated experience.
  • Efficient enrollment of subjects, low drop-out rate.
  • Quick start-up processes and efficient administration: we are flexible, responsive and willing to improve and develop together.
No. of new launched studies each year, working with major vaccine manufacturers/big pharma R&D10-15
Total no. of ongoing studies/ year27 (in 2022)
Average no. of new enrolled volunteers /year (top year)2,000-3,000 (top year for clinical trials 11,000, for pragmatic trials >30,000)
Study volunteer retentionapprox. 2% drop-out rate from studies

    Why conduct vaccine studies in Finland?

    • Educated and health-conscious people willing to participate in studies.
    • Exact enumeration of the population with potential to reach everyone.
    • High level of collaboration between public healthcare providers, enabling also large-scale pragmatic studies.
    • Extensive, high quality national health registers.
    The reach of our clinics is not limited to their location as we also reach neighboring municipalities
    City/townPopulation size, end-2022
    Espoo305,274
    Helsinki (2 clinics)664,028
    Järvenpää45,630
    Kokkola48,006
    Oulu211,848
    Pori83,205
    Seinäjoki65,323
    Tampere249,009
    Turku197,900
    (source: Statistics Finland)
    FVR’s network of ten clinics.
    Age % of tot. 5.6 million population
    0–1415.1
    15–6461.6
    65–8420.4
    85–2.9
    (source: statistics Finland)

    Contact us

    Mika Rämet, M.D., Ph.D., Professor of Paediatrics and Experimental Immunology
    Chief Medical Officer at FVR
    mika.ramet (at) fvr.fi 
    +358 50 433 6276

    Arto Palmu, M.D., Ph.D., University lecturer in clinical epidemiology
    Chief Research Officer at FVR
    arto.palmu (at) fvr.fi
    +358 50 549 7113

    • About us
      • Our role
      • BoD and management
      • Sustainability
    • For pharma sector
      • Research archive
    • Newsfeed
    • Contacts

    FVR - Finnish Vaccine Research
    Peltokatu 26, 33100 Tampere, Finland
    info@fvr.fi Business ID FI32566594

    • About cookies

    © Copyrights 2022 FVR – Finnish Vaccine Research